PMC:7228307 / 466-659 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"21","span":{"begin":117,"end":121},"obj":"Gene"}],"attributes":[{"id":"A21","pred":"tao:has_database_id","subj":"21","obj":"Gene:2213"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"apeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for "}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T9","span":{"begin":117,"end":119},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"}],"text":"apeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for "}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T4","span":{"begin":131,"end":139},"obj":"Chemical"}],"attributes":[{"id":"A4","pred":"chebi_id","subj":"T4","obj":"http://purl.obolibrary.org/obo/CHEBI_35224"}],"text":"apeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for "}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"21","span":{"begin":117,"end":121},"obj":"Gene"}],"attributes":[{"id":"A21","pred":"pubann:denotes","subj":"21","obj":"Gene:2213"}],"text":"apeutic monoclonal antibodies (mAbs) are approved or in late stage clinical trials, many of which harness the potent FcγR‐mediated effector systems to varying degrees. This is most evident for "}